Molecular Therapy - Nucleic Acids

Slides:



Advertisements
Similar presentations
Figure 1. Gene expression analysis
Advertisements

Molecular Therapy - Nucleic Acids
MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers  Thomas X. Lu,
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Characterization of microRNA transcriptome in tumor, adjacent, and normal tissues of lung squamous cell carcinoma  Jun Wang, MD, PhD, Zhi Li, MD, PhD,
MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers  Thomas X. Lu,
Accurate Molecular Characterization of Formalin-Fixed, Paraffin-Embedded Tissues by microRNA Expression Profiling  Anna E. Szafranska, Timothy S. Davison,
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Volume 17, Issue 5, Pages (May 2009)
Efficacy and Safety Profile of Tricyclo-DNA Antisense Oligonucleotides in Duchenne Muscular Dystrophy Mouse Model  Karima Relizani, Graziella Griffith,
Volume 21, Issue 6, Pages (June 2013)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Tween 85-Modified Low Molecular Weight PEI Enhances Exon-Skipping of Antisense Morpholino Oligomer In Vitro and in mdx Mice  Mingxing Wang, Bo Wu, Jason.
Volume 12, Issue 10, Pages (September 2015)
Volume 22, Issue 7, Pages (July 2014)
Volume 85, Issue 2, Pages (January 2014)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Methods & Clinical Development
Fig. 1. Generation of the ΔEx50 mouse model.
Molecular Therapy - Nucleic Acids
Helena M. Viola et al. BTS 2018;3:
Volume 26, Issue 1, Pages (January 2018)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Volume 23, Issue 8, Pages (August 2015)
Molecular Mechanisms Regulating the Defects in Fragile X Syndrome Neurons Derived from Human Pluripotent Stem Cells  Tomer Halevy, Christian Czech, Nissim.
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Volume 24, Issue 11, Pages (November 2016)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Volume 9, Issue 5, Pages (November 2017)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Volume 18, Issue 1, Pages (January 2010)
Volume 16, Issue 4, Pages (April 2008)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Volume 19, Issue 6, Pages (June 2011)
Volume 25, Issue 4, Pages (April 2017)
Transcriptional Repression of miR-34 Family Contributes to p63-Mediated Cell Cycle Progression in Epidermal Cells  Dario Antonini, Monia T. Russo, Laura.
Rational Design of Therapeutic siRNAs: Minimizing Off-targeting Potential to Improve the Safety of RNAi Therapy for Huntington's Disease  Ryan L Boudreau,
Volume 25, Issue 11, Pages (November 2017)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
A Collagen-based Scaffold Delivering Exogenous MicroRNA-29B to Modulate Extracellular Matrix Remodeling  Michael Monaghan, Shane Browne, Katja Schenke-Layland,
Volume 23, Issue 8, Pages (August 2015)
Fig. 1. Generation of the ΔEx50 mouse model.
Volume 9, Issue 4, Pages (October 2017)
Volume 25, Issue 4, Pages (April 2017)
MiRNA expression profiling in adipocytes from wild-type (WT) and leptin-deficient ob/ob mice. miRNA expression profiling in adipocytes from wild-type (WT)
Link between MHC Fiber Type and Restoration of Dystrophin Expression and Key Components of the DAPC by Tricyclo-DNA-Mediated Exon Skipping  Saleh Omairi,
Hepatocyte Growth Factor Regulates the miR-206-HDAC4 Cascade to Control Neurogenic Muscle Atrophy following Surgical Denervation in Mice  Wooshik Choi,
Molecular Therapy - Nucleic Acids
Loss of RNA-Binding Protein Sfpq Causes Long-Gene Transcriptopathy in Skeletal Muscle and Severe Muscle Mass Reduction with Metabolic Myopathy  Motoyasu.
Volume 17, Issue 5, Pages (May 2009)
Gang Han, Caorui Lin, Hanhan Ning, Xianjun Gao, HaiFang Yin 
Volume 8, Issue 1, Pages (July 2003)
Circular RNA Transcriptomic Analysis of Primary Human Brain Microvascular Endothelial Cells Infected with Meningitic Escherichia coli  Ruicheng Yang,
Molecular Therapy - Nucleic Acids
Chimeric Antisense Oligonucleotide Conjugated to α-Tocopherol
Volume 17, Issue 5, Pages (May 2009)
Molecular Therapy - Nucleic Acids
Aminoglycoside Enhances the Delivery of Antisense Morpholino Oligonucleotides In Vitro and in mdx Mice  Mingxing Wang, Bo Wu, Sapana N. Shah, Peijuan.
Presentation transcript:

Molecular Therapy - Nucleic Acids Expression Analysis in Multiple Muscle Groups and Serum Reveals Complexity in the MicroRNA Transcriptome of the mdx Mouse with Implications for Therapy  Thomas C Roberts, K Emelie M Blomberg, Graham McClorey, Samir EL Andaloussi, Caroline Godfrey, Corinne Betts, Thibault Coursindel, Michael J Gait, CI Edvard Smith, Matthew JA Wood  Molecular Therapy - Nucleic Acids  Volume 1, (January 2012) DOI: 10.1038/mtna.2012.26 Copyright © 2012 American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 MicroRNA (miRNA) transcriptome analysis. Quadriceps, diaphragm, and heart tissue from 8-week-old C57/Bl10 [wild type (WT)] and mdx mice (n = 4) were harvested and miRNA microarray analysis performed. (a) Heatmap of whole miRNA transcriptome of all three tissues for all miRNAs with a statistically significant (P < 0.05) change in expression between WT and mdx mice. (b) Scatter plot showing the relative spread of fold changes across all three tissues. The most upregulated and most downregulated miRNAs across all of the arrays are highlighted. (c) Venn diagram showing common changes in miRNA expression between the tissues. (d) Heatmap showing miRNAs with statistically significant expression changes in all three tissues. Hierarchical clustering analysis was used to identify patterns of miRNA expression in the mdx quadriceps, diaphragm, and heart. Red signifies an increase in expression and green, a decrease in expression. Heatmap scale bars indicate log2-fold changes. Molecular Therapy - Nucleic Acids 2012 1, DOI: (10.1038/mtna.2012.26) Copyright © 2012 American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Reverse transcription-quantitative PCR (RT-qPCR) analysis of dystromir expression. Tibialis anterior (TA), triceps, quadriceps, diaphragm, heart, and serum from 8-week-old C57/Bl10 [wild type (WT)] and mdx mice were harvested and small RNA TaqMan reverse transcriptase-quantitative PCR (RT-qPCR) performed to determine relative expression of the following dystromirs: (a) miR-1, (b) miR-21, (c) miR-29c, (d) miR-31, (e) miR-34c, (f) miR-133a, (g) miR-146b, (h) miR-199a-3p, (i) miR-206, (j) miR-221, (k) miR-223. Gray bars represent WT samples and black bars represent mdx samples. Relative fold changes were determined by the Pfaffl method. Tissue microRNA (miRNA) expression was normalized to miR-16 and serum miRNA expression normalized to miR-223 (consequently serum expression of miR-223 is omitted from panel (k)). All values are mean + SEM. *P < 0.05, **P < 0.01, ***P < 0.001. For tissue samples n = 4. For WT serum, n = 3 and for mdx serum n = 4. Molecular Therapy - Nucleic Acids 2012 1, DOI: (10.1038/mtna.2012.26) Copyright © 2012 American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Reverse transcription-quantitative PCR (RT-qPCR) analysis of dystromir expression. Tibialis anterior (TA), triceps, quadriceps, diaphragm, heart, and serum from 8-week-old C57/Bl10 [wild type (WT)] and mdx mice were harvested and small RNA TaqMan reverse transcriptase-quantitative PCR (RT-qPCR) performed to determine relative expression of the following dystromirs: (a) miR-1, (b) miR-21, (c) miR-29c, (d) miR-31, (e) miR-34c, (f) miR-133a, (g) miR-146b, (h) miR-199a-3p, (i) miR-206, (j) miR-221, (k) miR-223. Gray bars represent WT samples and black bars represent mdx samples. Relative fold changes were determined by the Pfaffl method. Tissue microRNA (miRNA) expression was normalized to miR-16 and serum miRNA expression normalized to miR-223 (consequently serum expression of miR-223 is omitted from panel (k)). All values are mean + SEM. *P < 0.05, **P < 0.01, ***P < 0.001. For tissue samples n = 4. For WT serum, n = 3 and for mdx serum n = 4. Molecular Therapy - Nucleic Acids 2012 1, DOI: (10.1038/mtna.2012.26) Copyright © 2012 American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 Heatmaps of mdx dystromir expression. Heatmaps of dystromir expression as determined by (a) microRNA (miRNA) microarray analysis and (b) small RNA TaqMan RT-qPCR. Hierarchical clustering analysis was used to identify patterns of miRNA expression across the mdx tissues and serum. Red signifies an increase in expression and green, a decrease in expression. Heatmap scale bars indicate log2-fold changes. Molecular Therapy - Nucleic Acids 2012 1, DOI: (10.1038/mtna.2012.26) Copyright © 2012 American Society of Gene & Cell Therapy Terms and Conditions

Figure 4 Differential expression of precursor-miRNAs and primary-miRNAs. (a) Statistically significant changes in precursor-miRNA (pre-miRNA) expression in mdx quadriceps, diaphragm, and heart (n = 4) as determined by microarray analysis. Hierarchical clustering analysis was used to identify patterns of pre-miRNA expression in the mdx quadriceps, diaphragm, and heart. Red signifies an increase in expression and green, a decrease in expression. Heatmap scale bars indicate fold changes. (b) Changes in primary-miRNA expression in mdx quadriceps for pri-miR-31, pri-miR-34c and pri-miR-206 as measured by RT-qPCR. Relative values were determined using the relative standard curve method and primary-miRNA expression normalized to PpiB. Values are mean + SEM, n = 4, * P < 0.05, ** P < 0.01. Molecular Therapy - Nucleic Acids 2012 1, DOI: (10.1038/mtna.2012.26) Copyright © 2012 American Society of Gene & Cell Therapy Terms and Conditions

Figure 5 Pip6e-phosphorodiamidate morpholino oligonucleotide (PMO) treatment normalizes serum dystromir abundance. Twelve-week-old mdx mice were injected with a single 12.5 mg/kg dose of Pip6e-PMO intravenously and harvested 2 weeks later. Serum samples were analyzed for the expression of (a) miR-1, (b) miR-133a, and (c) miR-206 by small RNA TaqMan RT-qPCR. miRNA levels were normalized to miR-223 expression and fold changes presented relative to the wild-type C57 average. (d) Representative immunofluorescence images of tibialis anterior muscle showing restoration of dystrophin at the sarcolemma in mdx mice following treatment with Pip6e-PMO. Samples were co-stained with laminin to indicate muscle fibers. (e) RT-PCR shows skipping of dystrophin exon 23 across various muscle groups. Values are mean ± SEM, n = 4, *P < 0.05. Molecular Therapy - Nucleic Acids 2012 1, DOI: (10.1038/mtna.2012.26) Copyright © 2012 American Society of Gene & Cell Therapy Terms and Conditions